不同级别脑膜瘤的临床病理特征和PR、ER、AR的表达差异分析

Abstract
Figure/Table
References (25)
Related Citation (15)

Download: PDF (779 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To study the clinicopathological characteristics of meningiomas (IM) and the expression differences of estrogen receptor (ER), progesterone receptor (PR), and androgen receptor (AR) in different grades of IM. Methods A retrospective study was conducted on 123 cases of IM treated in Hubei Provincial Hospital of Integrated Chinese & Western Medicine from May 2014 to November 2020. According to the different location, age, gender, tumor size, and invasion of IM, the tumor was re-classified and re-graded according to World Health Organization standards. The characteristics of recurrent cases were observed and the proliferation marker Ki67 was quantitatively analyzed. Immunohistochemical staining of ER, PR and AR was evaluated in some randomly selected cases. Results The proliferation index (PI) of Ki67 was highly positively correlated with grades of IM (r = 0.808, P ＜ 0.01), tumor size was slightly positively correlated with grades of IM (r = 0.257, P ＜ 0.01). The PI of grade Ⅱ IM was higher than that of grade Ⅰ with active cell growth, grade Ⅰ with active cell growth was higher than that of grade Ⅰ. The tumor size of grade Ⅱ IM was higher than that of grade Ⅰ, and there were statistically significant (P ＜ 0.05). The percentage of females was 79.7% (98 cases) was significantly higher than that of males 20.3% (25 cases). The positive rate of PR was 93.0% (53/57), the positive rate of AR was 63.3% (19/30), and no positive signal of ER was detected. There were no statistical differences in age distribution, location, invasion and histological types of patients with different grades (P ＞ 0.05). Conclusion PR may play an important role in the occurrence and development of IM. Some sex hormone drugs may affect the growth of the tumor. Individualized management is recommended. Relapsed cases have a tendency to increase tumor grades and PI. The combined analysis of PI, tumor size and histological morphology is helpful to comprehensively evaluate the biological behavior of IM.

Key words： Meningioma Proliferation index Estrogen Progesterone Androgen

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	GAO Ping1 XIANG Qingming2 YANG Yi1 ZONG Yangru1

Cite this article:

GAO Ping1 XIANG Qingming2 YANG Yi1 ZONG Yangru1. Clinicopathological characteristics and the differences analysis of expression of PR, ER and AR in different grades of meningiomas[J]. 中国医药导报, 2021, 18(22): 17-21.

URL:

https://www.yiyaodaobao.com.cn/EN/ OR https://www.yiyaodaobao.com.cn/EN/Y2021/V18/I22/17

[1] 赵越，程姣姣.孕激素受体膜组分1对激素诱导下乳腺癌增殖影响的实验研究[J].中国医药导报，2019，16（34）：11-14.
[2] Iplikcioglu AC，Hatiboglu MA，Ozek E，et al. Is progesteron receptor status really a prognostic factor for intracranial meningiomas? [J]. Clin Neurol Neurosurg，2014， 124：119-122.
[3] Maiuri F，Mariniello G，Guadagno E，et al. WHO grade，proliferation index，and progesterone receptor expression are different according to the location of meningioma [J]. Acta Neurochir （Wien），2019，161（12）：2553-2561.
[4] Louis DN，Perry A，Reifenberger G，et al. The 2016 World Health Organization Classification of Tumors of the Central Nervous System：a summary [J]. Acta Neuropathol，2016，131（6）：803-820.
[5] 张娇娇，宫惠琳.Ki67表达水平及TP53基因突变与IM术后复发相关性[J].中国肿瘤临床与康复，2018，25（2）：146-149.
[6] Ikeri NZ，Anunobi CC，Bankole OB. Progesterone receptor expression and Ki-67 labelling index of meningiomas in the Lagos university teaching hospital [J]. Niger Postgrad Med J，2018，25（1）：17-20.
[7] Ciocan LM，Dnil L，Stnculescu DE，et al. Prognostic factors in anterior skull base meningiomas [J]. Rom J Morphol Embryol，2014，55（3 Suppl）：1063-1069.
[8] Csonka Tamás，Murnyák Balázs，Rita S，et al. Assessment of candidate immunohistochemical prognostic markers of meningioma recurrence [J]. Folia neuropathologica，2016， 54（2）：114-126.
[9] He L，Yu S，Wang L. Rapid recurrence and malignant transformation of a benign meningioma after pregnancy：a case report [J]. Br J Neurosurg，2020，12：1-3.
[10] Chakravarthy V，Kaplan B，Gospodarev V，et al. The Houdini Tumor：A Case Report and Literature Review of Pregnancy Associated Meningiomas [J]. World Neurosurg，2018，114：e1261-e1265.
[11] Kerschbaumer J，Freyschlag CF，Stockhammer G，et al. Hormone-dependent shrinkage of a sphenoid wing meningioma after pregnancy：case report [J]. J Neurosurg，2016， 124（1）：137-140.
[12] 赵国芳.Ki67、CD34、PR免疫指标与WHOⅠ、Ⅱ级脑膜瘤MRI特征进行相关性对照研究[D].石家庄：河北医科大学（硕士学位论文），2020.
[13] Liu F，Chen W，Chen J. Letter to the Editor. Is there any relationship between estrogen receptor/progesterone receptor status and recurrence of meningioma? [J]. J Neurosurg，2018，128（6）：1899-1901.
[14] Mukhopadhyay M，Das C，Kumari M，et al. Spectrum of meningioma with special reference to prognostic utility of ER，PR and Ki67 expression [J]. J Lab Physicians，2017， 9（4）：308-313.
[15] Portet S，Banor T，Bousquet J，et al. New Insights into Expression of Hormonal Receptors by Meningiomas [J]. World Neurosurg，2020，140：e87-e96.
[16] Baxter DS，Orrego A，Rosenfeld JV，et al. An audit of immunohistochemical marker patterns in meningioma [J]. J Clin Neurosci，2014，21（3）：421-426.
[17] Koehorst SG，Jacobs HM，Thijssen JH，et al. Detection of an oestrogen receptor-like protein in human meningiomas by band shift assay using a synthetic oestrogen responsive element （ERE）[J]. Br J Cancer，1993，68（2）：290-294.
[18] Blankenstein MA，Verheijen FM，Jacobs JM，et al. Occurrence，regulation，and significance of progesterone receptors in human meningioma [J]. Steroids，2000，65（10/11）：795-800.
[19] Magdelenat H，Pertuiset BF，Poisson M，et al. Steroid receptor status difference in recurrent intracranial meningioma and breast cancer in the same patient [J]. J Neurooncol，1986，4（2）：155-157.
[20] Le?觔es CG，Meurer RT，Coutinho LB，et al. da Costa Oliveira M. Immunohistochemical expression of aromatase and estrogen，androgen and progesterone receptors in normal and neoplastic human meningeal cells [J]. Neuropathology，2010，30（1）：44-49.
[21] Shu X，Jiang Y，Wen T，et al. Association of hormone replacement therapy with increased risk of meningioma in women：A hospital-based multicenter study with propensity score matching [J]. Asia Pac J Clin Oncol，2019，15（5）：e147-e153.
[22] Alderman CP. Probable Drug-Related Meningioma Detected During the Course of Medication Review Services [J]. Consult Pharm，2016，31（9）：500-504.
[23] Bernat A L，Oyama K，Hamdi S，et al. Growth stabilization and regression of meningiomas after discontinuation of cyproterone acetate：a case series of 12 patients [J]. Acta Neurochir （Wien），2015，157（10）：1741-1746.
[24] Botella C，Coll G，Lemaire JJ，et al. Intra cranial meningiomas and long term use of cyproterone acetate with a conventional dose in women. A report of two cases of tumor decrease after treatment withdrawal [J]. Neurochirurgie，2015，61（5）：339-342.
[25] Altinoz MA，Ozpinar A，Elmaci I. Reproductive epidemiology of glial tumors may reveal novel treatments：high-dose progestins or progesterone antagonists as endocrino-immune modifiers against glioma [J]. Neurosurg Rev，2019，42（2）：351-369.